|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
LHGDN |
High prevalence of p53 exon 4 mutations in soft tissue sarcoma.
|
17429838 |
2007 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
To our knowledge, our patient is the first patient having a bone infarct-associated sarcoma with a p53 gene mutation.
|
22041521 |
2011 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
Molecular assessment of clonality leads to the identification of a new germ line TP53 mutation associated with malignant cystosarcoma phyllodes and soft tissue sarcoma.
|
10207667 |
1998 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
LHGDN |
In the absence of predisposition, TP53 was biallelically inactivated in one-third of the sarcomas, whereas at least one allele of RB1 was wild type.
|
17369843 |
2007 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
Germline TP53 mutations are found in Li-Fraumeni syndrome (LFS) patients, predisposed to soft tissue sarcoma and other malignancies.
|
21484931 |
2011 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
Sixty-two soft tissue sarcoma samples were investigated for the presence of p53 mutations and for p53 immunoreactivity.
|
8630896 |
1995 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
p53 gene mutations in soft-tissue sarcomas--correlations with p53 immunohistochemistry and DNA ploidy.
|
9177493 |
1997 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
The mutation status of TP53 and expression of MDM2, TP53, and their genetic variants SNP309 and R72P (Arg72Pro) were investigated in 125 sarcoma patient samples and 18 sarcoma cell lines.
|
23165797 |
2013 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
Germline alterations of the tumour suppressor TP53 gene are detected approximately in 25% of the families suggestive of Li-Fraumeni syndrome (LFS), characterised by a genetic predisposition to a wide tumour spectrum, including soft-tissue sarcomas, osteosarcomas, premenopausal breast cancers, brain tumours, adrenocortical tumours, plexus choroid tumours, leukaemia and lung cancer.
|
23612572 |
2013 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
The studies also explored the occurrence of de novo constitutional deletion of p53 in sporadic childhood sarcomas.
|
17136003 |
2006 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
Correlations of telomere length, P53 mutation, and chromosomal translocation in soft tissue sarcomas.
|
26191279 |
2015 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
These effectors were cross-reactive against sarcomas expressing p53 missense mutations outside of the p53(232-240) epitope, but not within it.
|
9419445 |
1998 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
These results demonstrated the dominance of the p53 mutations with null protein expression in bone and soft tissue sarcomas, showing a unique characteristic of these types of tumours compared with other malignancies such as colon carcinomas.
|
8260365 |
1993 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
Germline mutations of the p53 coding region are present in approximately 50-70% of patients with Li-Fraumeni Syndrome (LFS), a rare hereditary disorder of familial and intraindividual clustering of different malignancies such as sarcoma (index tumor), breast cancer, brain tumors, leukemias, and adrenocortical carcinomas, the latter usually in young children.
|
12200603 |
2002 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
In this study, we assess the apparent generation effect on cancer incidence in ten extended families with P53 germline mutation, identified through probands diagnosed with childhood sarcoma.
|
16284780 |
2005 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
Sarcomas represent a rational target for this approach given the high frequency of p53 mutations (40-75%) and MDM-2 amplification (10-30%).
|
15647767 |
2005 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
The sarcoma also harbored a somatic TP53 mutation: c.844C > T, p.R282W.
|
29315962 |
2018 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
Because these rare tumors also respond poorly to standard chemotherapy and bear a 50% 5-year mortality rate, we investigated the possible therapeutic benefits of p53 gene restoration in sarcomas.
|
10766348 |
2000 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline 'de-novo' TP53 mutation.
|
17572079 |
2007 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
New germline mutations of the p53 gene are rare among patients with "sporadic" sarcoma but may be common in patients with sarcoma whose background includes either multiple primary cancers or a family history of cancer.
|
1565143 |
1992 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk.
|
12610779 |
2003 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
LHGDN |
A high proportion (58%) of the radiation-induced sarcomas exhibited a somatic inactivating mutation for one allele of TP53, systematically associated with a loss of the other allele.
|
16492679 |
2006 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
The 3 families with TP53 mutations included cases of childhood sarcoma or brain tumors in addition to multiple cases of breast cancer.
|
16551709 |
2006 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
The present meta-analysis of currently available data suggests that the p53 codon 72 polymorphism may not play a role in sarcoma development in Caucasians.
|
24449505 |
2014 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
It is concluded that 17p deletions and TP53 mutations are common events in adult soft tissue sarcomas and that due to the trends observed with the cohort of patients analyzed they may become prognostic markers for patients affected with these tumors.
|
8053493 |
1994 |